TVRD vs CCHH Comparison

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.